• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Puretech Health Plc ADR (NQ: PRTC )

    19.70 UNCHANGED
    Streaming Delayed Price Updated: 2:20 PM EDT, Oct 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 19.70
    Bid (Size) 18.00 (1)
    Ask (Size) 30.90 (1)
    Prev. Close 19.70
    Today's Range 19.70 - 19.70
    52wk Range 17.08 - 34.00
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    PureTech to Present at CHEST 2024 Annual Meeting
    From PureTech Health
    Via Business Wire
    Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades
    Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The medication introduces a new approach by targeting M1 and M4 receptors without... 
    Via Benzinga
    Exposures Product Safety

    Performance

    YTD
    -21.20%
    -21.20%
    1 Month
    -9.22%
    -9.22%
    3 Month
    -10.58%
    -10.58%
    6 Month
    -33.67%
    -33.67%
    1 Year
    -3.19%
    -3.19%

    More News

    Read More
    Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies
    From PureTech Health plc
    Via Business Wire
    PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
    From PureTech Health plc
    Via Business Wire
    Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    PureTech Health plc – Half-Year Report
    From PureTech Health plc
    Via Business Wire
    Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    PureTech Appoints Michele Holcomb, PhD, to Board of Directors
    From PureTech Health plc
    Via Business Wire
    PureTech Health: Notice of Half-Yearly Results
    From PureTech Health plc
    Via Business Wire
    PureTech Founded Entity Seaport Therapeutics Appoints David Wheadon, M.D., to its Board of Directors
    From PureTech Health plc
    Via Business Wire
    PureTech Founded Entity Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
    From PureTech Health plc
    Via Business Wire
    PureTech Health: Completion of Tender Offer & Total Voting Rights
    From PureTech Health plc
    Via Business Wire
    PureTech Health: Results of the Tender Offer
    From PureTech Health plc
    Via Business Wire
    PureTech Announces Change of Board Role
    From PureTech Health plc
    Via Business Wire
    PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team
    From PureTech Health plc
    Via Business Wire
    PureTech Health: Results of Annual General Meeting
    From PureTech Health plc
    Via Business Wire
    PureTech Health: Result of General Meeting
    From PureTech Health plc
    Via Business Wire
    PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company
    From PureTech Health plc
    Via Business Wire
    PureTech to Present at the Jefferies Global Healthcare Conference
    From PureTech Health plc
    Via Business Wire
    PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
    From PureTech Health plc
    Via Business Wire
    PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share
    From PureTech Health plc
    Via Business Wire
    PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting
    From PureTech Health plc
    Via Business Wire
    PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments
    From PureTech Health plc
    Via Business Wire
    PureTech Announces Annual Results for Year Ended December 31, 2023
    From PureTech Health plc
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.